Athenex Inc

NASDAQ:ATNX  
1.01
-0.06 (-5.19%)
Debt Financing / Related, Earnings Announcements

Athenex Announces Agreement With ImmunityBio Regarding Dunkirk Manufacturing Facility

Published: 01/12/2022 14:19 GMT
Athenex Inc (ATNX) - Athenex Announces Agreement With Immunitybio Regarding Dunkirk Manufacturing Facility.
Athenex Inc - Agreement for Immunitybio, to Assume Its Leasehold Interest in a Manufacturing Facility in Dunkirk, and Some Assets for About $38 Million.
Athenex Inc - Immunitybio Will Assume All Capital Expenditure and Hiring Obligations of Athenex Pursuant to Its Agreements With New York State.
Athenex Inc - Proceeds From Sale Will Be Used to Service Company's Debt Obligations.
Athenex - Immunitybio Has Entered Into a Preliminary Agreement With Athenex to Allow Aps Ability to Manufacture Its 503b Products at Dunkirk Facility.
Revenue is expected to be $30.97 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $28.58 Million
Next Quarter EPS Guidance is expected to be -$0.27

More details on our Analysts Page.